A Comprehensive Review About SARS-CoV-2

Abstract

The coronavirus disease (COVID-19) was first identified in China, December 2019. Since then, it has spread the length and breadth of the world at an unprecedented, alarming rate. Severe acute respiratory syndrome coronavirus (SARS-CoV)-2, which causes COVID-19, has much in common with its closest homologs, SARS-CoV and Middle East respiratory syndrome-CoV. The virus–host interaction of SARS-CoV-2 uses the same receptor, ACE2, which is similar to that of SARS-CoV, which spreads through the respiratory tract. Patients with COVID-19 report symptoms including mild-to-severe fever, cough and fatigue; very few patients report gastrointestinal infections. There are no specific antiviral strategies. A few strong medications are under investigation, so we have to focus on proposals which ought to be taken to forestall this infection in a living host.

Graphical abstract

Keywords:

• coronavirus
• COVID-19
• inhibitors
• life cycle
• RNA
• SARS-CoV-2

View correction statement:

Corrigendum

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at:www.tandfonline.com/doi/full/10.2217/fvl-2020-0124

Author contributions

SKM Haque formulated the study and contributed with abstract, background, symptoms and behaviors, mechanism of viruses, inhibition, recommendation, advice, data interpretation, future perspective, executive summary and references. O Ashwaq participated with abstract, background, mechanism of viruses, future perspective, executive summary and references. A Sarief contributed with symptoms and behaviors, mechanism of viruses, recommendation, advice, future perspective and executive summary. AKAJ Mohamed participated with collection of data and created graphs, future perspective and references.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.